Show simple item record

dc.contributor.authorWelman, Arkadiusz
dc.contributor.authorBarraclough, Jane
dc.contributor.authorDive, Caroline
dc.date.accessioned2009-07-09T12:25:53Z
dc.date.available2009-07-09T12:25:53Z
dc.date.issued2006
dc.identifier.citationGeneration of cells expressing improved doxycycline-regulated reverse transcriptional transactivator rtTA2S-M2. 2006, 1 (2):803-11 Nat Protocen
dc.identifier.issn1750-2799
dc.identifier.pmid17406311
dc.identifier.doi10.1038/nprot.2006.117
dc.identifier.urihttp://hdl.handle.net/10541/73082
dc.description.abstractTet-on cell lines engineered to stably express doxycycline (Dox)-regulated reverse transcriptional transactivator (rtTA) have many applications in biomedical research and biotechnology. Unfortunately, construction and maintenance of such cells often proves to be costly, labor intensive and ineffective. Moreover, the Tet-on clones generated using standard methodology were often unstable and frequently displayed significantly changed physiological properties compared with their parental cells. Here we describe an optimized protocol for generation of Tet-on cells. The protocol is based on the use of a recently developed pN1p beta actin-rtTA2S-M2-IRES-EGFP vector (where IRES is an internal ribosome entry site) and permits relatively inexpensive construction of many Tet-on clones with essentially 100% efficiency. The method is well suited for 'difficult' cell lines displaying genetic instability and high levels of epigenetic silencing. The constructed Tet-on cells remain stable with time in the absence of any selection agents, are easy to monitor and preserve the characteristics of parental cells. The protocol can be completed in 2 months.
dc.language.isoenen
dc.subject.meshCell Line
dc.subject.meshDoxycycline
dc.subject.meshElectroporation
dc.subject.meshFlow Cytometry
dc.subject.meshGene Expression Regulation
dc.subject.meshGenetic Engineering
dc.subject.meshHumans
dc.subject.meshPlasmids
dc.subject.meshTrans-Activators
dc.subject.meshTransfection
dc.titleGeneration of cells expressing improved doxycycline-regulated reverse transcriptional transactivator rtTA2S-M2.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester, M20 4BX, United Kingdom. awelman@picr.man.ac.uken
dc.identifier.journalNature Protocolsen
html.description.abstractTet-on cell lines engineered to stably express doxycycline (Dox)-regulated reverse transcriptional transactivator (rtTA) have many applications in biomedical research and biotechnology. Unfortunately, construction and maintenance of such cells often proves to be costly, labor intensive and ineffective. Moreover, the Tet-on clones generated using standard methodology were often unstable and frequently displayed significantly changed physiological properties compared with their parental cells. Here we describe an optimized protocol for generation of Tet-on cells. The protocol is based on the use of a recently developed pN1p beta actin-rtTA2S-M2-IRES-EGFP vector (where IRES is an internal ribosome entry site) and permits relatively inexpensive construction of many Tet-on clones with essentially 100% efficiency. The method is well suited for 'difficult' cell lines displaying genetic instability and high levels of epigenetic silencing. The constructed Tet-on cells remain stable with time in the absence of any selection agents, are easy to monitor and preserve the characteristics of parental cells. The protocol can be completed in 2 months.


This item appears in the following Collection(s)

Show simple item record